Predictive Medicine by Cytomics
1. Problem:
2. Predictive Medicine by Cytomics
This permits to formulate a general concept for predictive
medicine by cytomics:
3. Data Collection
4. Multiparameter Data Pattern Classification
5. Examples
Diseases are caused by biochemical changes in
cellular systems or organs. They are induced by exposure
to external influences like microorganisms, allergens, toxic
substances a.o. or alternatively by genetic disposition
or genetic aberrations. Disease course prediction (>95% correct)
for individual patients is usually considered impossible for the
majority of diseases. Exceptions concern e.g. genotypic aberrations
detected during amniocentesis or preimplantation diagnostics (PID).
The substantial clinical interest in predicting the future
disease development in individual patients prompts for the search
of relevant information at the cellular level.
Considering genomics or proteomics for genome
or proteome analysis, the high multiparametric complexity and the
usual preanalytic content mixing from different cell
populations in cell or tissue extracts, constitute substantial
drawbacks for predictive conclusions in common diseases like
infections, allergies, malignancies, intoxications a.o.
Cytomics, the multiparameter cytometric analysis of the
cellular heterogeneity of cytomes (cellular systems/organs/body),
access a maximum of information on the apparent molecular cell
phenotypes, resulting from cell genotypes and exposure.
The cell phenotypes in the naturally existing cellular and cell
population heterogeneity of disease affected body cytomes contain
the information on the future development (prediction) as
well as on the present status (diagnosis) of a disease.
a.) multiparametric cytometric analysis of functions or
constituents in disease associated cytomes
b.) exhaustive numeric analysis of all measured cell populations for
>95% of the collected cells
c.) standardized data pattern classification
of the entire cellular information against the future disease course
of patients during the learning phase
d.) subsequent classification of an embedded test set of patient data,
measured under the same conditions as the learning set but unknown
to the learning process, followed by prospective classifications of
unknown patient data in the clinical application phase.
Patterns of various biomolecules can be reliably quantitated by cytometric
analysis of viable or fixed cells following staining with biochemically
specific fluorescent dyes. The particular effort of this laboratory
consists in the development of specific stains for
cell functions
in viable cells as sensitive indicators of the altered cellular
metabolism in acute or chronic disease. The simultaneous
multiparameter data collection by the cytometer provides high amounts
of functional and structural information on
heterogeneous i.e. essentially unprocessed ex-vivo cell suspensions
shortly after removal from the human body.
The cellular heterogeneity of human samples offers important
advantages for clinical and experimental
system cytometry
because the high information content of simultaneously
collected multiparameter data from a great variety of different
cell types can be utilized. The cytometric strategy is
explicitely to measure as much heterogeneity as possible to
profit during evaluation from the high information content of
biocomplexity. The cytometric approach is therefore quite
different from the tissue biochemistry approach where
one tries to reach as much homogeneity as possible e.g. by
the isolation of groups of similar cells by laser microdissection
to assure unambiguous interpretation of experimental results.
The exhaustive extraction of information from cytometric or clinical
chemistry multiparameter measurements by a laboratory and instrument
independent, self learning and
standardized
data classification algorithm, developed
earlier,
provides accurate single patient disease course prediction,
as well as diagnostics in case of sufficiently information
rich molecular data or other patient data.
Clinical examples
from several medical disciplines underline this point.
Predictive medicine by cytomics represents Evidence Based Medicine
(EBM) at the cellular level.
The practical consequence of this approach is that complications
in a number of common diseases like severe infections, shock,
exacerbation of rheumatoid and asthmatic disease,
thromboembolic complications in diabetes, myocardial infarction
and stroke sensitive patients or survival in cancer patients,
but also e.g. complications in bone marrow stem cell transplantation
(BM-SCT) will become increasingly predictable at the individual
patient level.
Minor interventions like cytometry supervised short term
antiphlogistic therapy e.g. just prior to an imminent exacerbation of
rheumatoid disease may prevent severe tissue destruction leading otherwise
to the stepwise disabling of the patient by deficient repair processes.
The cell biochemical approach has in this case the potential to
significantly postpone the invalidization of patients. The higher
quality of patients's life would be paralleled by shorter disease periods
at substantially lower therapy costs and a lower number
of unwanted therapeutic side effects (Optimized Medicine).
INTERNET:
https://www.classimed.de
© 2023 G.Valet
last update: Aug 02,2001
first display: Jan 29,1995